← Human Trials & Peer-Reviewed Studies
Comparison of the Efficacy of Tolterodine versus Oxybutynin in the Treatment of Children with Desmopressin-Resistant Enuresis: A Randomized Controlled Clinical Trial
Plain-language guide to PMID 38784212 (2023): randomized controlled trial study of Vasopressin and Desmopressin in 68 participants.
Key Facts
- PMID
- 38784212
- Journal
- Ethiopian journal of health sciences
- Year
- 2023
- Study type
- Randomized Controlled Trial
- Authors
- Ezodin N et al. (6 authors)
- DOI
- 10.4314/ejhs.v33i4.7
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Vasopressin and Desmopressin, published as a randomized controlled trial.
Enuresis, defined as involuntary nocturnal urination without any underlying organic disorder in a child expected to control urination, poses a common problem.
Who Took Part
The abstract describes 68 participants taking part.
PubMed indexes the participants as young children, children and teenagers, both men and women.
A randomized clinical trial was undertaken involving 68 participants aged between 5 and 16 years, all suffering from primary enuresis.
These patients were randomly assigned to one of two treatment groups for a three-month period: Group 1, treated with Oxybutynin and Desmopressin, and Group 2, treated with Tolterodine and Desmopressin.
How the Study Was Run
In design terms this was a randomized study.
Because people in this Vasopressin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
The methods mention a period of three months.
Data on demographics, clinical and laboratory findings, and subjective responses to treatment were gathered.
The response was measured based on the frequency of wetting incidents per night and week and compared with pre-treatment data.
What Was Measured
PubMed files the paper under topics including Tolterodine Tartrate, Mandelic Acids, Deamino Arginine Vasopressin, Nocturnal Enuresis, Muscarinic Antagonists, Antidiuretic Agents and Urological Agents.
Author keywords: Desmopressin and Oxybutynin.
What This Means in Plain Language
The paper is a randomized study of Vasopressin and Desmopressin in 68 participants over three months.
Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2023 (Ethiopian journal of health sciences), a journal based in Ethiopia.
More context: the Vasopressin compound page and the Desmopressin compound page, all human trials.
Our Notes on the Compounds
Vasopressin: A 9-amino-acid hormone (antidiuretic hormone) that controls water balance and blood vessel tone; used in septic shock.
Desmopressin: A synthetic vasopressin analog (DDAVP) used for bedwetting, diabetes insipidus and some bleeding disorders.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.